Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
0.4320
+0.0322 (8.05%)
At close: Jun 15, 2026, 4:00 PM EDT
0.4600
+0.0280 (6.48%)
Pre-market: Jun 16, 2026, 5:31 AM EDT
Cytosorbents Revenue
Cytosorbents had revenue of $8.86M in the quarter ending March 31, 2026, with 1.57% growth. This brings the company's revenue in the last twelve months to $19.10M, up 9.44% year-over-year. In the year 2025, Cytosorbents had annual revenue of $37.06M with 4.12% growth.
Revenue (ttm)
$19.10M
Revenue Growth
+9.44%
P/S Ratio
0.73
Revenue / Employee
$288,372
Employees
129
Market Cap
27.09M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 37.06M | 1.47M | 4.12% |
| Dec 31, 2024 | 35.60M | 4.51M | 14.51% |
| Dec 31, 2023 | 31.09M | -3.60M | -10.39% |
| Dec 31, 2022 | 34.69M | -8.48M | -19.64% |
| Dec 31, 2021 | 43.17M | 2.16M | 5.27% |
| Dec 31, 2020 | 41.00M | 16.06M | 64.35% |
| Dec 31, 2019 | 24.95M | 2.45M | 10.87% |
| Dec 31, 2018 | 22.50M | 7.35M | 48.53% |
| Dec 31, 2017 | 15.15M | 5.62M | 59.02% |
| Dec 31, 2016 | 9.53M | 4.74M | 98.84% |
| Dec 31, 2015 | 4.79M | 668.79K | 16.22% |
| Dec 31, 2014 | 4.12M | 1.70M | 70.18% |
| Dec 31, 2013 | 2.42M | 1.08M | 80.40% |
| Dec 31, 2012 | 1.34M | 1.31M | 3,622.32% |
| Dec 31, 2011 | 36.08K | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
| Dec 31, 2006 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 428.57M |
| TELA Bio | 80.81M |
| IRIDEX | 52.58M |
| Baird Medical Investment Holdings | 22.54M |
| Lifeward | 20.92M |
| NeuroOne Medical Technologies | 12.72M |
| Pulsenmore | 12.55M |
| InspireMD | 10.85M |
CTSO News
- 4 days ago - Cytosorbents Proxy statement: Proxy filing - Filings
- 4 weeks ago - CytoSorbents reports Q1 adjusted EPS (5c) vs. (6c) last year - TheFly
- 4 weeks ago - Cytosorbents Earnings Call Transcript: Q1 2026 - Transcripts
- 4 weeks ago - Cytosorbents Earnings release: Q1 2026 - Filings
- 4 weeks ago - Cytosorbents Quarterly report: Q1 2026 - Filings
- 4 weeks ago - Cytosorbents Slides: Q1 2026 - Filings
- 4 weeks ago - CytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update - PRNewsWire
- 6 weeks ago - CytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights - PRNewsWire